Bound Therapeutics is a cutting-edge biotechnology company focused on creating RNA-based therapies for rare, hard-to-treat diseases, with an emphasis on oncology. Our proprietary platform, Magic Bullet Designer (MBD), leverages AI and machine learning to enhance the tissue-specific delivery of RNA therapeutics, ensuring precision and efficacy. Currently in the preclinical phase, our pipeline includes innovative treatments for aggressive cancers and genetic disorders, positioning Bound Therapeutics as a leader in next-generation RNA therapeutics.
We have demonstrated single agent in vivo proof-of-concept efficacy and safety in an aggressive breast cancer mouse model with our lead molecule BND6482, targeting microRNA-21, a cancer-driving RNA overexpressed in all solid tumors. We are expanding our pipeline to include lung, colon, prostate, and brain cancers.
Revolutionize medicine by leveraging RNA therapeutics and AI-driven delivery technologies to tackle diseases with unmet needs, providing innovative solutions globally.
Leverage AI-optimized RNA-peptide bioconjugates to precisely target disease drivers, delivering effective, low-toxicity treatments that redefine the standard of care and offer new hope.
At Bound Therapeutics, we are revolutionizing RNA therapeutics with our AI-optimized nanocomplexes that precisely target disease-causing molecules, focusing on drug-resistant triple-negative breast cancer. Our unique platform combines innovative chemistry, proprietary delivery, and deep scientific expertise to transform patient care.
Bound Therapeutics is different by the core of the business model, as we are striving with all heads strong aiming to do great things
Bound Therapeutics is different by the core of the business model, as we are striving with all heads strong aiming to do great things
Bound Therapeutics is different by the core of the business model, as we are striving with all heads strong aiming to do great things
Bound Therapeutics is different by the core of the business model, as we are striving with all heads strong aiming to do great things
Bound Therapeutics is different by the core of the business model, as we are striving with all heads strong aiming to do great things
We develop personalized RNA-peptide cancer therapies targeting underserved markets using our AI-optimized platform
Bound Therapeutics LLC executed an exclusive license from Thomas Jefferson University to use our novel platform technology (Compositions and Methods of Using MicroRNA Inhibitors, PCT/US2015/015681) to develop microRNA therapeutics and diagnostics.
Preliminary data showed that our proprietary lead compound designed using our platform reversed off-target effects from conventionally designed microRNA-blocking agents in a triple negative breast cancer cell model.
Bound Therapeutics agents achieve cancer cell-specific delivery of the lead compound through receptor-mediated endocytosis by conjugation with a small peptide (Wickstrom and Basu, Peptide Nucleic Acid Conjugates. U.S. 6,180,767, 2001).
Our platform yields single molecule agents that circulate and enter cells with no need for liposome or nanoparticle formulations. We will optimize agents for the needs of each target and customer.
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer, accounting for 20% of cases and affecting 40,000 U.S. women annually. Existing treatments have significant limitations, leaving patients with few options. The only available supplemental therapy, Avastin, was invalidated by the FDA in 2011 due to poor outcomes and safety issues.
Bound Therapeutics is addressing this critical unmet need with its AI-optimized RNA-peptide nanocomplex technology. This platform enables the development of personalized, targeted therapies that can precisely deliver cancer-fighting agents to tumor cells, minimizing off-target effects and improving efficacy compared to conventional treatments.
Drugs in the TNBC pipeline, such as PARP inhibitors and immune checkpoint blockers, have shown only modest effectiveness in a small subset of patients. Bound Therapeutics’ novel approach offers an attractive option, with a projected annual market potential of $2.8 billion, to transform the standard of care for this devastating disease.
MicroRNA therapeutics is a growing field with a market size of $70.5 million as of 2013 and a compound annual growth rate (CAGR) of 14.9%. Bound Therapeutics LLC will focus on commercializing our lead compound in triple negative breast cancer. The initial developmental phase from lead optimization to phase I clinical safety trial will be supported by non-dilutive federal research grants in parallel with venture capital placements. Our exit strategy lies in acquisition by a pharmaceutical firm with a broad breast cancer therapeutics portfolio to complete phase II/III trials and commercialize the lead compound within 10 years.
In the long term, Bound Therapeutics will increase revenue by branching out to other markets including lung cancer, cardiovascular disease, and diabetes. These chronic diseases display high incidence in the U.S., with 224,000 new cases for lung cancer, 720,000 for heart disease, and 1.7 million for diabetes annually. We will develop compounds for each indication in alliances with pharmaceutical companies to broaden their pipeline. We will generate additional profit from joint ventures and royalty payments with each compound.
On 27 April, the USPTO allowed our application for “Bound Therapeutics” as a registered trademark. We will use the “BND” prefix on each of our candidate leads and tool compounds. For example, BND4037 blocks the miR-17-5p guide strand, without imitating the activity of the miR-17-3p passenger strand.
Bound Therapeutics is different by the core of the business model, as we are striving with all heads strong aiming to do great things
Exepdite FDA Approval. Complete the initial stages of development from proof-of-concept to lead optimization with non-dilutive capital by obtaining federal Small Business Innovative Research funding. In parallel, we will secure venture capital to take our lead compound all the way through a phase I clinical safety trial.
Develop individual compounds applicable to each therapeutic indication in alliances with pharmaceutical companies that are determined to broaden their pipeline. We will generate additional profit from joint ventures and royalty payments with each compound.
Commercialize our lead compound for triple negative breast cancer as a proof-of-principle for our platform.
Expand our pipeline of microRNA-blocking or supplementation agents to other therapeutic markets, such as lung cancer, cardiovascular disease, and diabetes.
Bound Therapeutics is different by the core of the business model, as we are striving with all heads strong aiming to do great things
Compositions and methods for MYC messenger RNA inhibitors (PCT/US2018/049055)
Compositions and Methods for the Treatment of Cancer (PCT/US2024/019719)
Compositions and Methods for the Treatment of Coronavirus Infection (US17/470676)
Bound Therapeutics is led by a seasoned team of biotech leaders with deep expertise in AI-driven drug discovery, organic chemistry, molecular and structural biology, clinical pharmacology, and successful pharmaceutical commercialization.
Ready to be part of groundbreaking research that enhances lifespan and quality of life for patients and their families? Join us on this transformative journey!
Bound Therapeutics
Cambridge Innovation Center (CIC)
3675 Market Street, Suite 200
Philadelphia, PA 19104
Connect with us to learn more about our technology and explore partnership opportunities.
Bound Therapeutics
Cambridge Innovation Center (CIC)
3675 Market Street, Suite 200
Philadelphia, PA 19104
